SHANGHAI FOSUN PHARMACEUTICAL Aktie

 

Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal Key Takeaways:    By Molly Wen It's becoming a familiar story: the Chinese drugs industry has signed another licensing deal with Big Pharma to fast track a weight-loss treatment. This time..... The post Lagging in the weight-loss market? Take Fosun's GLP-1 pill appeared first on Bamboo Works....

Shanghai Fosun Pharmaceutical Group Co. announced plans to acquire a controlling stake in a Chinese company that developed the country's first indigenous therapy for Alzheimer's disease only to wind up later suspending sales and production....

Boston, MA (www.aktiencheck.de) - Pfizer-Aktienanalyse von Leerink Partners: David Risinger, Analyst von Leerink Partners, stuft die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) mit "market perform" ein. Pfizer habe am 9. Dezember 2025 bekannt gegeben, eine exklusive globale Kollaborations- und Lizenzvereinbarung mit YaoPharma, einer Tochtergesellschaft von Fosun Pharma, für YP05002 abgeschlossen zu haben - einen GLP-1RA-Small-Molecule-Kandidaten in Phase 1. [mehr]...

US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including......

FOSUN PHARMA (02196.HK) signed a US$2.1 billion collaboration agreement with Pfizer (PFE.US) for its preclinical small molecule GLP-1 drug. Due to Pfizer's active involvement and long-term arrangement in the GLP-1 field, this collaboration gives YP05002 a leading position, CLSA released a research report saying. Compared to ......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Pfizer Inc. has entered into an exclusive global collaboration and licensing deal with a unit of Shanghai Fosun Pharmaceutical (Group) Co. for an early-stage weight-loss drug....

SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have......

FOSUN INTL (00656.HK) is participating in the China International Import Expo (CIIE) for eight years in a row. The company, alongside its overseas member enterprises and global partners, is showcasing innovative pharmaceuticals, high-end medical devices, and international collaboration achievements at the FOSUN PHARMA (02196.HK)......

Fangzhou and Fosun Pharma plan to build partnership in AI-powered chronic disease management, initially focused on psoriasis and other autoimmune condition...

Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding RMB6,700 Million in The First Three Quarters of 2025 SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group";......

FOSUN PHARMA (02196.HK) announced that its operating revenue for the third quarter this year was RMB9.879 billion, down 5.46% YoY. The net profit attributable to shareholders was RMB821 million, up 4.52% YoY, with an EPS of RMB0.31.~AASTOCKS Financial NewsWebsite: www.aastocks.com...

Driven by accelerating healthcare demand, Fosun Health plans to target markets in South Asia, Southeast Asia and the Middle East to capitalise on their economic growth and fragmented health systems, according to chairman and CEO Frank Hu Hang. The subsidiary of Hong Kong-listed Shanghai Fosun Pharmaceutical (Group) operates 19 hospitals, clinics and third-party diagnostics centres in mainland China. Four of these are in Foshan, Guangzhou, Shenzhen and Zhuhai – cities that are part of the Greater......

Citi wrote in its research report that it had had a meeting with Guan Xiaohui, Co-Chairman of FOSUN PHARMA (02196.HK). Considering the company's attractive employee stock ownership plan targets, innovative pipeline valuation, and potential operational leverage effects, the broker raised its target price from HKD25 to HKD35.3......

Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms including Johnson & Johnson and Roche Holding about selling them the rights to an experimental cancer drug, people familiar with the matter said. An agreement could fetch the subsidiary of Shanghai Fosun Pharmaceutical at least several hundred million dollars up front and then more in milestone payments down the road based on the drug's performance, the people said. They asked not to be identified because the......

At midday close, HSI rose 90 pts or 0.4% to 25,508. HSTI rose 15 pts or 0.3% to 5,702. HSCEI gained 15 pts or 0.2% to 9,072.Active Heavyweights:BABA (09988.HK) closed at $136.7, up 3.7%XIAOMI (01810.HK) closed at $54.3, up 1.2%TENCENT (00700.HK) closed at $612, up 1.1%MEITUAN (03690.HK) closed at $102.5, down 0.5%HSI & HSCEI Con......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Enhancing Innovation Efficiency and Steadily Expanding Globally SHANGHAI, Aug. 26, 2025 /PRNewswire/ -- On August 26, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company,......

FOSUN PHARMA (02196.HK) opened up 7.55% today and once peaked at HKD21.16. It last traded at HKD20.66, up 6.83%, on a volume of 6.4764 million shares and a turnover of HKD135 million.The company announced yesterday (11th) that its controlling subsidiary, Fosun Pharmaceutical Industrial, has granted Expedition the rights to devel......

Following a joint U.S.-China statement announcing a further 90-day suspension of reciprocal 24% tariffs, Hong Kong bourse opened lower as markets awaited U.S. inflation data. The HSI dipped 82 points or 0.3% to 24,824, the HSCEI dropped 30 points or 0.3% to 8,858, and the HSTECH declined 32 points or 0.6% to 5,427.For techs, BAB......